Detomax™

Dexmedetomidine IV infusion

Presentation
Detomax™ IV infusion: Each vial contains Dexmedetomidine Hydrochloride USP equivalent to Dexmedetomidine 200 mcg. Each normal saline bottle contains 48 ml 0.9% Sodium Chloride solution.

Description
Dexmeditomidine is a relatively selective alpha2-adrenergic agonist with sedative properties.

Indication
Dexmeditomidine is a relatively selective alpha2-adrenergic agonist indicated for:

- Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Administer Dexmeditomidine by continuous infusion not to exceed 24 hours.
- Sedation of non-intubated patients prior to and/or during surgical and other procedures.

Dosage and Administration

- Individualize and titrate Dexmeditomidine dosing to desired clinical effect.
- Administer Dexmeditomidine using a controlled infusion device.
- Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration.
- The 200 mcg/50mL single-use bottles do not require further dilution prior to administration.

For Adult Intensive Care Unit Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour.

For Adult Procedural Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour.
Alternative Doses: Recommended for patients over 65 years of age and awake fiberoptic intubation patients.

Use in Pregnancy and Lactation
Pregnancy Category C

Side-effects

Body System	Disease/Symptom
Body as a Whole	Fever, hyperpyrexia, hypovolemia, light anesthesia, pain, rigors
Cardiovascular Disorders, General	Blood pressure fluctuation, heart disorder, hypertension, hypotension, myocardial infarction
Central and Peripheral Nervous System Disorders	Dizziness, headache, neuralgia, neuritis, speech disorder, convulsion
Gastrointestinal System Disorders	Abdominal pain, diarrhea, vomiting, nausea
Liver and Biliary System Disorders	Increased gamma-glutamyl transpeptidase, hepatic function abnormal, hyperbilirubinemia
Metabolic and Nutritional Disorders	Acidosis, respiratory acidosis, hyperkalemia, thirst, hypoglycemia
Psychiatric Disorders	Agitation, confusion, delirium, hallucination, illusion
Red Blood Cell Disorders	Anemia
Renal Disorders	Blood urea nitrogen increased, oliguria
Respiratory System Disorders	Hypoventilation, hypoxia, pulmonary congestion
Skin Disorders	Increased sweating
Vascular Disorders	Hemorrhage
Vision Disorders	Photopsia, abnormal vision

Contraindications
Contraindicated with none.

Precautions
Continuous monitoring is needed while patient receiving Dexmedetomidine.

Drug Interactions
Co-administration of Dexmedetomidine with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.

Overdose
Bradycardia, hypotension and cardiac arrest is observed.

Commercial Packaging
Detomax™ IV infusion: Each pack contains one vial (2 ml) with carton, 48 ml normal saline in a glass bottle, one infusion set, hanger and one 5 ml disposable syringe.

Manufactured by
Incepta Pharmaceuticals Ltd
Savar, Dhaka, Bangladesh

VN 01

DTV